TENX is an ultra-low float biotech with one treatment its pipeline.
Levosimendan will go into a Ph2 study to treat PH-HFpEF during H-2/18.
PH-HFpEF is high blood pressure in the arteries supplying the lung. Presently, there is no approved drug for this condition. Supplemental O2 is used to alleviate symptoms.
Levo is a compound with a a 16-yr history of use in Europe. Its inotropic and lusitropic properties are an indication that it may work in PH-HFpEF.
12/31/17 Cash = $9.5mn. Burn has been ~$1.6mn / Q ; but, expenses will increase significantly when the Ph2 begins during H2/18.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.